Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.52 |
| ▸ | IL1RN | P18510 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30271245 | 0.97 | ERAP1 (0.54) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL30414279 | 0.96 | OPRM1 (0.58) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL29619512 | 0.95 | OPRM1 (0.52) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL30797170 | 0.95 | OPRM1 (0.57) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL29577523 | 0.94 | ERAP1 (0.56) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL29577107 | 0.94 | ERAP1 (0.56) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL7048052 | 0.94 | ERAP1 (0.57) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL7936370 | 0.94 | ERAP1 (0.57) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL7048050 | 0.94 | ERAP1 (0.57) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL30582610 | 0.93 | ERAP2 (0.52) | ERAP2ERAP1LNPEPIL1RN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4237012-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | Avacta Life Sciences Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094262-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |